BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.Nat Rev Gastroenterol Hepatol. 2019;16:185-196. [PMID: 30478416 DOI: 10.1038/s41575-018-0084-8] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Kvedaraite E, Lourda M, Han H, Tesi B, Mitchell J, Ideström M, Mouratidou N, Rassidakis G, von Bahr Greenwood T, Cohen-Aubart F, Jädersten M, Åkefeldt SO, Svensson M, Kannourakis G, Bryceson YT, Haroche J, Henter JI. Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23. Acta Paediatr 2021;110:1315-21. [PMID: 32975844 DOI: 10.1111/apa.15590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hou G, Bishu S. Th17 Cells in Inflammatory Bowel Disease: An Update for the Clinician. Inflamm Bowel Dis 2020;26:653-61. [PMID: 31970388 DOI: 10.1093/ibd/izz316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
3 Cantorna MT, Rogers CJ, Arora J. Aligning the Paradoxical Role of Vitamin D in Gastrointestinal Immunity. Trends Endocrinol Metab 2019;30:459-66. [PMID: 31122825 DOI: 10.1016/j.tem.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Consonni FM, Porta C, Marino A, Pandolfo C, Mola S, Bleve A, Sica A. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. Front Immunol 2019;10:949. [PMID: 31130949 DOI: 10.3389/fimmu.2019.00949] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
5 Selin KA, Hedin CRH, Villablanca EJ. Immunological networks defining the heterogeneity of inflammatory bowel diseases. J Crohns Colitis 2021:jjab085. [PMID: 33959743 DOI: 10.1093/ecco-jcc/jjab085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Tait Wojno ED, Hunter CA, Stumhofer JS. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity 2019;50:851-70. [PMID: 30995503 DOI: 10.1016/j.immuni.2019.03.011] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 33.7] [Reference Citation Analysis]
7 Riva A, Gray EH, Azarian S, Zamalloa A, McPhail MJW, Vincent RP, Williams R, Chokshi S, Patel VC, Edwards LA. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep 2020;2:100151. [PMID: 32838247 DOI: 10.1016/j.jhepr.2020.100151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
8 Nigam GB, Limdi JK. An update on the role of anti-IL-12/IL23 agents in the management of inflammatory bowel disease. Br Med Bull 2021;138:29-40. [PMID: 33884410 DOI: 10.1093/bmb/ldab001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Caër C, Wick MJ. Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease. Front Immunol 2020;11:410. [PMID: 32256490 DOI: 10.3389/fimmu.2020.00410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
10 Yang T, Cui X, Tang M, Qi W, Zhu Z, Shi M, Yang L, Pei H, Zhang W, Xie L, Xu Y, Yang Z, Chen L. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2022. [PMID: 35113547 DOI: 10.1021/acs.jmedchem.1c01137] [Reference Citation Analysis]
11 Qian B, Wang C, Zeng Z, Ren Y, Li D, Song JL. Ameliorative Effect of Sinapic Acid on Dextran Sodium Sulfate- (DSS-) Induced Ulcerative Colitis in Kunming (KM) Mice. Oxid Med Cell Longev 2020;2020:8393504. [PMID: 33312339 DOI: 10.1155/2020/8393504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Xuan L, Ren L, Han F, Gong L, Wan Z, Yang S, Liu H, Lv Y, Liu L. Cytomegalovirus Infection Exacerbates Experimental Colitis by Promoting IL-23 Production. Inflammation 2020;43:326-35. [PMID: 31701354 DOI: 10.1007/s10753-019-01122-x] [Reference Citation Analysis]
13 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
15 Zhao N, Dong W, Kim H, Moallemian R, Lv J, Wang H, Zheng H, Wei F, Ma X. Capping protein regulator and myosin 1 linker 3 regulates transcription of key cytokines in activated phagocytic cells. Cell Signal 2021;78:109848. [PMID: 33246003 DOI: 10.1016/j.cellsig.2020.109848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Li K, Dong J, Ge D, Li M, Ye H, Wang X, Wu Y. The Effects of Sishen Wan on T Cell Responses in Mice Models of Ulcerative Colitis Induced by Dextran Sodium Sulfate. Evid Based Complement Alternat Med 2021;2021:9957709. [PMID: 34956391 DOI: 10.1155/2021/9957709] [Reference Citation Analysis]
17 Chengxiao Y, Dongmei W, Kai Z, Hou L, Xiao H, Ding T, Liu D, Ye X, Linhardt RJ, Chen S. Challenges of pectic polysaccharides as a prebiotic from the perspective of fermentation characteristics and anti-colitis activity. Carbohydr Polym 2021;270:118377. [PMID: 34364621 DOI: 10.1016/j.carbpol.2021.118377] [Reference Citation Analysis]
18 Solà-Tapias N, Vergnolle N, Denadai-Souza A, Barreau F. The Interplay Between Genetic Risk Factors and Proteolytic Dysregulation in the Pathophysiology of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:1149-61. [PMID: 32090263 DOI: 10.1093/ecco-jcc/jjaa033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the Pipeline? J Crohns Colitis 2022;16:ii64-72. [PMID: 35553666 DOI: 10.1093/ecco-jcc/jjab185] [Reference Citation Analysis]
20 Trzupek D, Dunstan M, Cutler AJ, Lee M, Godfrey L, Jarvis L, Rainbow DB, Aschenbrenner D, Jones JL, Uhlig HH, Wicker LS, Todd JA, Ferreira RC. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Med 2020;12:55. [PMID: 32580776 DOI: 10.1186/s13073-020-00756-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
21 Ghavami SB, Yadegar A, Aghdaei HA, Sorrentino D, Farmani M, Mir AS, Azimirad M, Balaii H, Shahrokh S, Zali MR. Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease. Int J Mol Sci 2020;21:E6266. [PMID: 32872480 DOI: 10.3390/ijms21176266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ho J, Camilli G, Griffiths JS, Richardson JP, Kichik N, Naglik JR. Candida albicans and candidalysin in inflammatory disorders and cancer. Immunology 2021;162:11-6. [PMID: 32880925 DOI: 10.1111/imm.13255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Chen W, Liu D, Ren C, Su X, Wong C, Yang R. A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis. Cells 2022;11:307. [DOI: 10.3390/cells11020307] [Reference Citation Analysis]
24 Ju J, Dai Y, Yang J, Liu C, Fan L, Feng L, Zhao B, Zeng M, Liu Z, Sun X. Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterol 2020;20:340. [PMID: 33059618 DOI: 10.1186/s12876-020-01474-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mishra J, Stubbs M, Kuang L, Vara N, Kumar P, Kumar N, Subramanian VS. Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Mediators of Inflammation 2022;2022:1-15. [DOI: 10.1155/2022/9621668] [Reference Citation Analysis]
26 Luo X, Villablanca EJ. Type 2 immunity in intestinal homeostasis and inflammatory bowel disease. Biochem Soc Trans 2021;49:2371-80. [PMID: 34581755 DOI: 10.1042/BST20210535] [Reference Citation Analysis]
27 Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F. ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis 2019;10:315. [PMID: 30962426 DOI: 10.1038/s41419-019-1540-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
28 Yang W, Gibson SA, Yan Z, Wei H, Tao J, Sha B, Qin H, Benveniste EN. Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitis. Mucosal Immunol 2020;13:788-98. [PMID: 31988467 DOI: 10.1038/s41385-020-0258-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
29 Ji E, Lee S. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. Int J Mol Sci 2021;22:5770. [PMID: 34071276 DOI: 10.3390/ijms22115770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Shao J, Xu Z, Xu Y. Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35442011 DOI: 10.1007/s13318-022-00768-7] [Reference Citation Analysis]
31 Tarumi Y, Mori T, Okimura H, Maeda E, Tanaka Y, Kataoka H, Ito F, Koshiba A, Kusuki I, Kitawaki J. Interleukin-9 produced by helper T cells stimulates interleukin-8 expression in endometriosis. Am J Reprod Immunol 2021;86:e13380. [PMID: 33210782 DOI: 10.1111/aji.13380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
33 Binienda A, Ziolkowska S, Hauge IH, Salaga M. The Role of Immune and Epithelial Stem Cells in Inflammatory Bowel Disease Therapy. Curr Drug Targets 2020;21:1405-16. [PMID: 32364073 DOI: 10.2174/1389450121666200504074922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
34 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Pastor-Fernández G, Mariblanca IR, Navarro MN. Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Cells 2020;9:E2044. [PMID: 32906785 DOI: 10.3390/cells9092044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
36 Eftychi C, Schwarzer R, Vlantis K, Wachsmuth L, Basic M, Wagle P, Neurath MF, Becker C, Bleich A, Pasparakis M. Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity 2019;51:367-380.e4. [PMID: 31350179 DOI: 10.1016/j.immuni.2019.06.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
37 Zhang J, Chen G, Liang S, Liu J, Zhang J, Shen H, Chen Y, Duan J, Sun Z. PM2.5 exposure exaggerates the risk of adverse birth outcomes in pregnant women with pre-existing hyperlipidemia: Modulation role of adipokines and lipidome. Sci Total Environ 2021;787:147604. [PMID: 33992945 DOI: 10.1016/j.scitotenv.2021.147604] [Reference Citation Analysis]
38 Kwak MS, Lee HH, Cha JM, Shin HP, Jeon JW, Yoon JY. Novel candidate drugs in anti-tumor necrosis factor refractory Crohn's diseases: in silico study for drug repositioning. Sci Rep 2020;10:10708. [PMID: 32612148 DOI: 10.1038/s41598-020-67801-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, De Vos M, Van den Bosch F, Elewaut D. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020;16:415-33. [PMID: 32661321 DOI: 10.1038/s41584-020-0454-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
40 Gao J, Cui J, Zhong H, Li Y, Liu W, Jiao C, Gao J, Jiang C, Guo W, Xu Q. Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice via decreasing inflammation and fibrosis. Int Immunopharmacol 2020;83:106426. [PMID: 32220806 DOI: 10.1016/j.intimp.2020.106426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
41 Cohen NA, Rubin DT. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol 2021;37:357-63. [PMID: 34059604 DOI: 10.1097/MOG.0000000000000740] [Reference Citation Analysis]
42 Gaglio SC, Donini M, Denbaes PE, Dusi S, Perduca M. Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles. Molecules 2021;26:2106. [PMID: 33916909 DOI: 10.3390/molecules26082106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Mu X, Fardy J, Reid S, Trahey J. Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis. BMC Gastroenterol 2021;21:361. [PMID: 34600483 DOI: 10.1186/s12876-021-01936-w] [Reference Citation Analysis]
44 Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology 2022:S0016-5085(22)00102-0. [PMID: 35134323 DOI: 10.1053/j.gastro.2022.01.047] [Reference Citation Analysis]
45 Boardman DA, Garcia RV, Ivison SM, Bressler B, Dhar TM, Zhao Q, Levings MK. Pharmacological inhibition of RORC2 enhances human Th17‐Treg stability and function. Eur J Immunol 2020;50:1400-11. [DOI: 10.1002/eji.201948435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
46 Lv L, Jiang H, Yan R, Xu D, Wang K, Wang Q, Chen X, Li L. The Salivary Microbiota, Cytokines, and Metabolome in Patients with Ankylosing Spondylitis Are Altered and More Proinflammatory than Those in Healthy Controls. mSystems 2021;6:e0117320. [PMID: 34156295 DOI: 10.1128/mSystems.01173-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol 2020;175:113928. [PMID: 32217101 DOI: 10.1016/j.bcp.2020.113928] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
48 Gamah M, Alahdal M, Zhang Y, Zhou Y, Ji Q, Yuan Z, Han Y, Shen X, Ren Y, Zhang W. High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes. Bioengineered 2021;12:7985-94. [PMID: 34666625 DOI: 10.1080/21655979.2021.1975017] [Reference Citation Analysis]
49 [DOI: 10.1101/855486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Chen JA, Ma H, Liu Z, Tian J, Lu S, Fang W, Ze S, Lu W, Xie Q, Huang J, Wang Y. Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease. J Med Chem 2021. [PMID: 34957834 DOI: 10.1021/acs.jmedchem.1c01746] [Reference Citation Analysis]
51 Amerikanou C, Dimitropoulou E, Gioxari A, Papada E, Tanaini A, Fotakis C, Zoumpoulakis P, Kaliora AC. Linking the IL-17A immune response with NMR-based faecal metabolic profile in IBD patients treated with Mastiha. Biomed Pharmacother 2021;138:111535. [PMID: 34311533 DOI: 10.1016/j.biopha.2021.111535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kvedaraite E. Neutrophil-T cell crosstalk in inflammatory bowel disease. Immunology 2021. [PMID: 34240423 DOI: 10.1111/imm.13391] [Reference Citation Analysis]
53 Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021;6:255. [PMID: 34234112 DOI: 10.1038/s41392-021-00679-0] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
54 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Morita Y, Imai T, Bamba S, Takahashi K, Inatomi O, Miyazaki T, Watanabe K, Nakamura S, Yoshida A, Endo Y, Ohmiya N, Tsujikawa T, Andoh A. Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease. J Gastroenterol Hepatol 2020;35:1163-70. [PMID: 31860733 DOI: 10.1111/jgh.14962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Loh JT, Lee KG, Lee AP, Teo JKH, Lim HL, Kim SS, Tan AH, Lam KP. DOK3 maintains intestinal homeostasis by suppressing JAK2/STAT3 signaling and S100a8/9 production in neutrophils. Cell Death Dis 2021;12:1054. [PMID: 34743196 DOI: 10.1038/s41419-021-04357-5] [Reference Citation Analysis]
57 Zhang C, Qi W, Li Y, Tang M, Yang T, Liu K, Chen Y, Deng D, Xiang M, Chen L. Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem 2021;64:1966-88. [PMID: 33593051 DOI: 10.1021/acs.jmedchem.0c01468] [Reference Citation Analysis]
58 Cheon SY, Lee JE. Extracellular Vesicles and Immune System in Ageing and Immune Diseases. Exp Neurobiol 2021;30:32-47. [PMID: 33632983 DOI: 10.5607/en20059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G, Iannone F. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne) 2021;8:737079. [PMID: 34631754 DOI: 10.3389/fmed.2021.737079] [Reference Citation Analysis]
60 Zhang L, Gui S, Xu Y, Zeng J, Wang J, Chen Q, Su L, Wang Z, Deng R, Chu F, Liu W, Jin X, Lu X. Colon tissue-accumulating mesoporous carbon nanoparticles loaded with Musca domestica cecropin for ulcerative colitis therapy. Theranostics 2021;11:3417-38. [PMID: 33537095 DOI: 10.7150/thno.53105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020;69:1335-42. [PMID: 32303609 DOI: 10.1136/gutjnl-2020-321269] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 54.0] [Reference Citation Analysis]
62 Lucaciu LA, Ilieș M, Vesa ȘC, Seicean R, Din S, Iuga CA, Seicean A. Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. J Pers Med 2021;11:1130. [PMID: 34834482 DOI: 10.3390/jpm11111130] [Reference Citation Analysis]
63 Murate K, Maeda K, Nakamura M, Sugiyama D, Wada H, Yamamura T, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Miyahara R, Ishigami M, Nishikawa H, Fujishiro M. Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. Inflamm Bowel Dis 2020;26:1669-81. [PMID: 32405651 DOI: 10.1093/ibd/izaa086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Ostanek B, Drobne D, Grabnar I. Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 2021;13:1587. [PMID: 34683880 DOI: 10.3390/pharmaceutics13101587] [Reference Citation Analysis]
65 Ickrath F, Stoevesandt J, Schulmeyer L, Glatzel C, Goebeler M, Kerstan A. Metastatischer Morbus Crohn: eine unterschätzte Entität. J Dtsch Dermatol Ges 2021;19:973-82. [PMID: 34288476 DOI: 10.1111/ddg.14447_g] [Reference Citation Analysis]
66 Morosi LG, Cutine AM, Cagnoni AJ, Manselle-Cocco MN, Croci DO, Merlo JP, Morales RM, May M, Pérez-Sáez JM, Girotti MR, Méndez-Huergo SP, Pucci B, Gil AH, Huernos SP, Docena GH, Sambuelli AM, Toscano MA, Rabinovich GA, Mariño KV. Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits. Sci Adv 2021;7:eabf8630. [PMID: 34144987 DOI: 10.1126/sciadv.abf8630] [Reference Citation Analysis]
67 Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, Gasbarrini A, Franceschi F. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:6242. [PMID: 34200555 DOI: 10.3390/ijms22126242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Xiao T, Zhang P, Feng T, Lu K, Wang X, Zhou S, Qiang Y. Butyrate functions in concert with myeloid-derived suppressor cells recruited by CCR9 to alleviate DSS-induced murine colitis. Int Immunopharmacol 2021;99:108034. [PMID: 34426112 DOI: 10.1016/j.intimp.2021.108034] [Reference Citation Analysis]
69 Oliveira RG, Damazo AS, Antonielli LF, Miyajima F, Pavan E, Duckworth CA, Lima JCDS, Arunachalam K, Martins DTO. Dilodendron bipinnatum Radlk. extract alleviates ulcerative colitis induced by TNBS in rats by reducing inflammatory cell infiltration, TNF-α and IL-1β concentrations, IL-17 and COX-2 expressions, supporting mucus production and promotes an antioxidant effect. J Ethnopharmacol 2021;269:113735. [PMID: 33359865 DOI: 10.1016/j.jep.2020.113735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Floss DM, Moll JM, Scheller J. IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells 2020;9:E2184. [PMID: 32998371 DOI: 10.3390/cells9102184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
71 Mo Q, Liu T, Fu A, Ruan S, Zhong H, Tang J, Zhao M, Li Y, Zhu S, Cai H, Feng F. Novel Gut Microbiota Patterns Involved in the Attenuation of Dextran Sodium Sulfate-Induced Mouse Colitis Mediated by Glycerol Monolaurate via Inducing Anti-inflammatory Responses. mBio 2021;12:e0214821. [PMID: 34634946 DOI: 10.1128/mBio.02148-21] [Reference Citation Analysis]
72 Ramser A, Greene E, Wideman R, Dridi S. Local and Systemic Cytokine, Chemokine, and FGF Profile in Bacterial Chondronecrosis with Osteomyelitis (BCO)-Affected Broilers. Cells 2021;10:3174. [PMID: 34831397 DOI: 10.3390/cells10113174] [Reference Citation Analysis]
73 Bilsborough J, Fiorino MF, Henkle BW. Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis. Expert Opin Drug Discov 2021;16:567-77. [PMID: 33245673 DOI: 10.1080/17460441.2021.1851185] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Horuluoglu BH, Kayraklioglu N, Tross D, Klinman D. PAM3 protects against DSS-induced colitis by altering the M2:M1 ratio. Sci Rep 2020;10:6078. [PMID: 32269253 DOI: 10.1038/s41598-020-63143-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
75 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Reference Citation Analysis]
76 Kanazawa N, Wada Y, Akiyama M, Shikida Y, Sugiyama M, Abe M, Iyoda M, Honda K, Shibata T. Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report. CEN Case Rep 2020;9:204-9. [PMID: 32100251 DOI: 10.1007/s13730-020-00457-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Lee YM, Seo SH, Cho SY, Choi DH, Cheon MW, Kim HY, Youn DH, Pak SC, Son HS, Na CS. Herbal Medicine and Acupuncture Combined Treatment Attenuates Colitis in Rats. Am J Chin Med 2021;49:965-82. [PMID: 33827383 DOI: 10.1142/S0192415X21500464] [Reference Citation Analysis]
78 Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World J Gastrointest Oncol 2022; 14(3): 547-567 [DOI: 10.4251/wjgo.v14.i3.547] [Reference Citation Analysis]
79 Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
80 He S, Cui S, Song W, Jiang Y, Chen H, Liao D, Lu X, Li J, Chen X, Peng L. Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota. mBio 2022;:e0368821. [PMID: 35266816 DOI: 10.1128/mbio.03688-21] [Reference Citation Analysis]
81 Tran S, Prober DA. Validation of Candidate Sleep Disorder Risk Genes Using Zebrafish. Front Mol Neurosci 2022;15:873520. [DOI: 10.3389/fnmol.2022.873520] [Reference Citation Analysis]
82 Ojo BA, VanDussen KL, Rosen MJ. The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis. Inflamm Bowel Dis 2021:izab161. [PMID: 34251431 DOI: 10.1093/ibd/izab161] [Reference Citation Analysis]
83 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
84 Sewell GW, Kaser A. Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. J Crohns Colitis 2022;16:ii3-ii19. [PMID: 35553667 DOI: 10.1093/ecco-jcc/jjac034] [Reference Citation Analysis]
85 Yuan YY, Liu YJ, Fan H. New progress in research of Th17 cells and related cytokines in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(24): 1402-1409 [DOI: 10.11569/wcjd.v29.i24.1402] [Reference Citation Analysis]
86 Wu L, Hollinshead KER, Hao Y, Au C, Kroehling L, Ng C, Lin WY, Li D, Silva HM, Shin J, Lafaille JJ, Possemato R, Pacold ME, Papagiannakopoulos T, Kimmelman AC, Satija R, Littman DR. Niche-Selective Inhibition of Pathogenic Th17 Cells by Targeting Metabolic Redundancy. Cell 2020;182:641-654.e20. [PMID: 32615085 DOI: 10.1016/j.cell.2020.06.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
87 Ickrath F, Stoevesandt J, Schulmeyer L, Glatzel C, Goebeler M, Kerstan A. Metastatic Crohn's disease: an underestimated entity. J Dtsch Dermatol Ges 2021;19:973-82. [PMID: 33960613 DOI: 10.1111/ddg.14447] [Reference Citation Analysis]
88 Rosenbaum JT, Karstens L. Bugs, Drugs, and Shrugs. Arthritis Rheumatol 2020;72:515-7. [PMID: 31736274 DOI: 10.1002/art.41166] [Reference Citation Analysis]
89 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Reference Citation Analysis]
90 Wang J, Lv M, He L, Wang X, Lan Y, Chen J, Chen M, Zhang C, Tang R, Zhou D, Deng X, Li J, Guo T, Price M, Yue B, Fan Z. Transcriptomic landscape of persistent diarrhoea in rhesus macaques and comparison with humans and mouse models with inflammatory bowel disease. Gene 2021;800:145837. [PMID: 34274469 DOI: 10.1016/j.gene.2021.145837] [Reference Citation Analysis]
91 Chung SH, Ye XQ, Iwakura Y. Interleukin-17 family members in health and disease. Int Immunol 2021;33:723-9. [PMID: 34611705 DOI: 10.1093/intimm/dxab075] [Reference Citation Analysis]
92 Hernández-cabanyero C, Sanjuán E, Reyes-lópez FE, Vallejos-vidal E, Tort L, Amaro C. A Transcriptomic Study Reveals That Fish Vibriosis Due to the Zoonotic Pathogen Vibrio vulnificus Is an Acute Inflammatory Disease in Which Erythrocytes May Play an Important Role. Front Microbiol 2022;13:852677. [DOI: 10.3389/fmicb.2022.852677] [Reference Citation Analysis]
93 Caminero A, Pinto-Sanchez MI. Host immune interactions in chronic inflammatory gastrointestinal conditions. Curr Opin Gastroenterol 2020;36:479-84. [PMID: 32868507 DOI: 10.1097/MOG.0000000000000673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Nourbakhsh E, Mohammadi A, Salemizadeh Parizi M, Mansouri A, Ebrahimzadeh F. Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target. Inflammopharmacology 2021. [PMID: 34283371 DOI: 10.1007/s10787-021-00846-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021;398:803-16. [PMID: 34454676 DOI: 10.1016/S0140-6736(21)00438-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Pisarska MM, Dunne MR, O'shea D, Hogan AE. Interleukin‐17 producing mucosal associated invariant T cells ‐ emerging players in chronic inflammatory diseases? Eur J Immunol 2020;50:1098-108. [DOI: 10.1002/eji.202048645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther 2019;50:373-85. [DOI: 10.1111/apt.15397] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
98 Feng Y, Chen Z, Tu S, Wei J, Hou Y, Kuang Z, Kang X, Ai H. Role of Interleukin-17A in the Pathomechanisms of Periodontitis and Related Systemic Chronic Inflammatory Diseases. Front Immunol 2022;13:862415. [DOI: 10.3389/fimmu.2022.862415] [Reference Citation Analysis]
99 Ullrich KA, Schulze LL, Paap EM, Müller TM, Neurath MF, Zundler S. Immunology of IL-12: An update on functional activities and implications for disease. EXCLI J 2020;19:1563-89. [PMID: 33408595 DOI: 10.17179/excli2020-3104] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
100 Jensen BAH, Holm JB, Larsen IS, von Burg N, Derer S, Sonne SB, Pærregaard SI, Damgaard MV, Indrelid SA, Rivollier A, Agrinier AL, Sulek K, Arnoldussen YJ, Fjære E, Marette A, Angell IL, Rudi K, Treebak JT, Madsen L, Åkesson CP, Agace W, Sina C, Kleiveland CR, Kristiansen K, Lea TE. Lysates of Methylococcus capsulatus Bath induce a lean-like microbiota, intestinal FoxP3+RORγt+IL-17+ Tregs and improve metabolism. Nat Commun 2021;12:1093. [PMID: 33597537 DOI: 10.1038/s41467-021-21408-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
102 Rao RR, Majlessipour F, Ziring DA, Baca NM. Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report. J Adolesc Young Adult Oncol 2021;10:614-7. [PMID: 32960134 DOI: 10.1089/jayao.2020.0077] [Reference Citation Analysis]
103 Cui J, Li Y, Jiao C, Gao J, He Y, Nie B, Kong L, Guo W, Xu Q. Improvement of magnesium isoglycyrrhizinate on DSS-induced acute and chronic colitis. Int Immunopharmacol 2021;90:107194. [PMID: 33290965 DOI: 10.1016/j.intimp.2020.107194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov 2021;7:52. [PMID: 33723241 DOI: 10.1038/s41420-021-00437-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
105 Parigi SM, Das S, Frede A, Cardoso RF, Tripathi KP, Doñas C, Hu YOO, Antonson P, Engstrand L, Gustafsson JÅ, Villablanca EJ. Liver X receptor regulates Th17 and RORγt+ Treg cells by distinct mechanisms. Mucosal Immunol 2021;14:411-9. [PMID: 32681027 DOI: 10.1038/s41385-020-0323-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Balboa MA, de Pablo N, Meana C, Balsinde J. The role of lipins in innate immunity and inflammation. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:1328-37. [DOI: 10.1016/j.bbalip.2019.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
107 Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs 2020;34:713-21. [PMID: 33105016 DOI: 10.1007/s40259-020-00451-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
108 An Z, Flores-Borja F, Irshad S, Deng J, Ng T. Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer. Front Immunol 2019;10:3111. [PMID: 32117199 DOI: 10.3389/fimmu.2019.03111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
109 Katkar GD, Sayed IM, Anandachar MS, Castillo V, Vidales E, Toobian D, Usmani F, Sawires JR, Leriche G, Yang J, Sandborn WJ, Das S, Sahoo D, Ghosh P. Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol 2022;5:231. [PMID: 35288651 DOI: 10.1038/s42003-022-03168-4] [Reference Citation Analysis]
110 Gu Z, Tseng K, Tsai Y. Candida gut commensalism and inflammatory disease. Medicine in Microecology 2020;3:100008. [DOI: 10.1016/j.medmic.2020.100008] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A, Cheng L, Gillooly KM, Shuster D, Zhang Y, Thankappan A, McIntyre KW, Chaudhry C, Elzinga PA, Chiney M, Chimalakonda A, Lombardo LJ, Macor JE, Carter PH, Burke JR, Weinstein DS. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem 2021;64:677-94. [PMID: 33370104 DOI: 10.1021/acs.jmedchem.0c01698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
112 Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, Pengam S, Teppaz G, Thepenier V, Danger R, Robert-Siegwald G, Néel M, Bruneau S, Glémain A, Néel A, Poupon A, Mosnier JF, Chêne G, Dubourdeau M, Blancho G, Vanhove B, Poirier N. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Sci Adv 2021;7:eabd1453. [PMID: 33811066 DOI: 10.1126/sciadv.abd1453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Hirano T, Hirayama D, Wagatsuma K, Yamakawa T, Yokoyama Y, Nakase H. Immunological Mechanisms in Inflammation-Associated Colon Carcinogenesis. Int J Mol Sci 2020;21:E3062. [PMID: 32357539 DOI: 10.3390/ijms21093062] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
114 Yang H, Cai R, Kong Z, Chen Y, Cheng C, Qi S, Gu B. Teasaponin Ameliorates Murine Colitis by Regulating Gut Microbiota and Suppressing the Immune System Response. Front Med (Lausanne) 2020;7:584369. [PMID: 33363184 DOI: 10.3389/fmed.2020.584369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Majster M, Lira-Junior R, Höög CM, Almer S, Boström EA. Salivary and Serum Inflammatory Profiles Reflect Different Aspects of Inflammatory Bowel Disease Activity. Inflamm Bowel Dis 2020;26:1588-96. [PMID: 32725166 DOI: 10.1093/ibd/izaa190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Uchiyama K, Takagi T, Mizushima K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Tanaka M, Hotta Y, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Naito Y, Itoh Y. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterol 2021;21:122. [PMID: 33730998 DOI: 10.1186/s12876-021-01709-5] [Reference Citation Analysis]
117 Álvarez-Salamero C, Castillo-González R, Pastor-Fernández G, Mariblanca IR, Pino J, Cibrian D, Navarro MN. IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics. PLoS Biol 2020;18:e3000646. [PMID: 32203518 DOI: 10.1371/journal.pbio.3000646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
118 El-Gedamy M, El-Khayat Z, Abol-Enein H, El-Said A, El-Nahrery E. Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis. Immunogenetics 2021;73:207-26. [PMID: 33665735 DOI: 10.1007/s00251-021-01205-w] [Reference Citation Analysis]
119 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
120 Allard-Chamard H, Mishra HK, Nandi M, Mayhue M, Menendez A, Ilangumaran S, Ramanathan S. Interleukin-15 in autoimmunity. Cytokine 2020;136:155258. [PMID: 32919253 DOI: 10.1016/j.cyto.2020.155258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021;12:622934. [PMID: 33859636 DOI: 10.3389/fimmu.2021.622934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
122 Hanžel J, D'Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther 2020;20:399-406. [PMID: 31760827 DOI: 10.1080/14712598.2020.1697227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
123 Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol 2019;12:1756284819853208. [PMID: 31205488 DOI: 10.1177/1756284819853208] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
124 Elemam NM, Ramakrishnan RK, Hundt JE, Halwani R, Maghazachi AA, Hamid Q. Innate Lymphoid Cells and Natural Killer Cells in Bacterial Infections: Function, Dysregulation, and Therapeutic Targets. Front Cell Infect Microbiol 2021;11:733564. [PMID: 34804991 DOI: 10.3389/fcimb.2021.733564] [Reference Citation Analysis]
125 Uffelmann E, Huang QQ, Munung NS, de Vries J, Okada Y, Martin AR, Martin HC, Lappalainen T, Posthuma D. Genome-wide association studies. Nat Rev Methods Primers 2021;1. [DOI: 10.1038/s43586-021-00056-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
126 Goulart RA, Barbalho SM, Lima VM, Souza GA, Matias JN, Araújo AC, Rubira CJ, Buchaim RL, Buchaim DV, Carvalho ACA, Guiguer ÉL. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review. J Med Food 2021;24:675-85. [PMID: 33155879 DOI: 10.1089/jmf.2020.0129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Yang Y, He XR, He SG, Liu M, Zhang YX, Xia F, Cao MJ, Su WJ, Liu GM. Two allergens from Scylla paramamosain share common epitopes showed different allergenic potential in Balb/c mice. Food Chem 2022;371:131132. [PMID: 34555704 DOI: 10.1016/j.foodchem.2021.131132] [Reference Citation Analysis]
128 Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019;15:747-57. [PMID: 31551538 DOI: 10.1038/s41584-019-0294-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
129 Zhang Y, Liang R, Xie A, Shi W, Huang H, Zhong Y. Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway. Mediators Inflamm 2020;2020:1719467. [PMID: 32410846 DOI: 10.1155/2020/1719467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Han Y, Wang C, Klinger K, Rajpal DK, Zhu C. An integrative network-based approach for drug target indication expansion. PLoS One 2021;16:e0253614. [PMID: 34242265 DOI: 10.1371/journal.pone.0253614] [Reference Citation Analysis]
131 Orimo K, Tamari M, Saito H, Matsumoto K, Nakae S, Morita H. Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases. Allergy 2021. [PMID: 33866593 DOI: 10.1111/all.14863] [Reference Citation Analysis]
132 Zhang Z, Zhang H, Chen T, Shi L, Wang D, Tang D. Regulatory role of short-chain fatty acids in inflammatory bowel disease. Cell Commun Signal 2022;20:64. [PMID: 35546404 DOI: 10.1186/s12964-022-00869-5] [Reference Citation Analysis]
133 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Reference Citation Analysis]
134 De Pasquale C, Campana S, Bonaccorsi I, Carrega P, Ferlazzo G. ILC in chronic inflammation, cancer and targeting with biologicals. Mol Aspects Med 2021;:100963. [PMID: 33726947 DOI: 10.1016/j.mam.2021.100963] [Reference Citation Analysis]
135 Lavoie S, Conway KL, Lassen KG, Jijon HB, Pan H, Chun E, Michaud M, Lang JK, Gallini Comeau CA, Dreyfuss JM, Glickman JN, Vlamakis H, Ananthakrishnan A, Kostic A, Garrett WS, Xavier RJ. The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. Elife. 2019;8:e39982. [PMID: 30666959 DOI: 10.7554/elife.39982] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
136 Hwang S, Feng D, Gao B. Interleukin-22 acts as a mitochondrial protector. Theranostics 2020;10:7836-40. [PMID: 32685023 DOI: 10.7150/thno.48022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Xu L, Xie R, Xie H, Ju J, Fu X, Di D, Peng M, Gao W, Zhang Y, Yu D, Liu J, Yang G, Liu Z, Liu Z, Yang P. Chimeric specific antigen epitope‐carrying dendritic cells induce interleukin‐17(+) regulatory T cells to suppress food allergy. Clin Exp Allergy 2019;50:231-43. [DOI: 10.1111/cea.13528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
138 Harris RJ, McDonnell M, Young D, Bettey M, Downey L, Pigott L, Felwick R, Gwiggner M, Cummings JRF. Early real-world effectiveness of ustekinumab for Crohn's disease. Frontline Gastroenterol 2020;11:111-6. [PMID: 32133109 DOI: 10.1136/flgastro-2019-101237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
139 Truong SL, Chin J, Liew DFL, Zahir SF, Ryan EG, Rubel D, Radford-Smith G, Robinson PC. Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. Rheumatol Ther 2021;8:1603-16. [PMID: 34449067 DOI: 10.1007/s40744-021-00360-6] [Reference Citation Analysis]
140 Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1632-1643. [PMID: 32520312 DOI: 10.1093/ecco-jcc/jjaa120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
141 Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Owczarek D, Cibor D, Pocztar H, Mach T, Solnica B. Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. Arch Med Sci 2021;17:252-7. [PMID: 33488879 DOI: 10.5114/aoms/130842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Jing X, Korchagina AA, Shein SA, Muraoka WT, Koroleva E, Tumanov AV. IL-23 Contributes to Campylobacter jejuni-Induced Intestinal Pathology via Promoting IL-17 and IFNγ Responses by Innate Lymphoid Cells. Front Immunol 2020;11:579615. [PMID: 33488580 DOI: 10.3389/fimmu.2020.579615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Moisset X, Giraud P, Dallel R. Migraine in multiple sclerosis and other chronic inflammatory diseases. Rev Neurol (Paris) 2021:S0035-3787(21)00616-0. [PMID: 34325914 DOI: 10.1016/j.neurol.2021.07.005] [Reference Citation Analysis]
144 Suri K, Bubier JA, Wiles MV, Shultz LD, Amiji MM, Hosur V. Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells 2021;10:2204. [PMID: 34571853 DOI: 10.3390/cells10092204] [Reference Citation Analysis]
145 Cobb LM, Verneris MR. Therapeutic manipulation of innate lymphoid cells. JCI Insight 2021;6:146006. [PMID: 33749662 DOI: 10.1172/jci.insight.146006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Byrne LW, McKay D. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review. Surgeon 2021;19:e153-67. [PMID: 34581275 DOI: 10.1016/j.surge.2020.09.001] [Reference Citation Analysis]
147 Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. Clin Gastroenterol Hepatol 2021;19:111-118.e10. [PMID: 32109630 DOI: 10.1016/j.cgh.2020.02.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]